Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre hospitalier de l'Université de Montréal (CHUM)
University of Colorado, Denver
City of Hope Medical Center
Novartis
Var2 Pharmaceuticals
UNC Lineberger Comprehensive Cancer Center
A2 Biotherapeutics Inc.
Sahlgrenska University Hospital
City of Hope Medical Center
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Columbia University
Stanford University
Rutgers, The State University of New Jersey
Stanford University
Mansoura University
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
Sun Yat-sen University
Charite University, Berlin, Germany
Corvus Pharmaceuticals, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Klus Pharma Inc.
Eastern Cooperative Oncology Group
MacroGenics
RenJi Hospital
Wake Forest University Health Sciences
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Institut Bergonié
Abramson Cancer Center at Penn Medicine
Abramson Cancer Center at Penn Medicine
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Fox Chase Cancer Center
RenJi Hospital
City of Hope Medical Center
University Hospital Tuebingen
Stanford University
Instituto do Cancer do Estado de São Paulo
University of Iowa
Maastricht Radiation Oncology
Stanford University
Johns Hopkins Bloomberg School of Public Health
Washington University School of Medicine
Johns Hopkins Bloomberg School of Public Health
Northwestern University
Duke University
National Cancer Institute (NCI)